Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anil Shinde

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 22, 2017
Erratum to: An RCT Investigating Patient-Driven Versus Physician-Driven Titration of BIAsp 30 in Patients with Type 2 Diabetes Uncontrolled Using NPH InsulinAbdelmjid Chraibi, Shoorook Al-Herz, Bich Dao Nguyen, et al.
Expert Opinion on Investigational Drugs|February 23, 2026
Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist, as a potential treatment for narcolepsy: a phase-2 Drug evaluationRamakrishna Nirogi, Anil Shinde, Ramkumar Subramanian, et al.
Cureus|June 1, 2026
Assessment of Sexual Behaviour Among HIV-Syphilis Coinfected Individuals From Designated Sexually Transmitted Infection/Reproductive Tract Infection (STI/RTI) Clinics in Mumbai, IndiaLatika Shivkar, Shrikala Acharya, Shwetangi R Shinde, et al.
Bioorganic & Medicinal Chemistry Letters|July 5, 2011
Rigidized 1-aryl sulfonyl tryptamines: synthesis and pharmacological evaluation as 5-HT6 receptor ligandsRamakrishna Nirogi, Adireddy Dwarampudi, Ramasastry Kambhampati, et al.
Biomolecules|February 25, 2023
Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain DisordersRamakrishna Nirogi, Pradeep Jayarajan, Anil Shinde, et al.
Neurology and Therapy|July 31, 2022
Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled StudyRamakrishna Nirogi, Vinod Kumar Goyal, Vijay Benade, et al.
Clinical Drug Investigation|August 13, 2022
Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly SubjectsRamakrishna Nirogi, Vijay Benade, Vinod Kumar Goyal, et al.
European Journal of Medicinal Chemistry|January 6, 2016
Benzamide derivatives and their constrained analogs as histamine H3 receptor antagonistsRamakrishna Nirogi, Anil Shinde, Vinaykumar Tiriveedhi, et al.
Behavioural Pharmacology|May 31, 2018
SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterizationRamakrishna Nirogi, Renny Abraham, Vijay Benade, et al.
Bioorganic & Medicinal Chemistry Letters|October 6, 2012
N,N-Dimethyl-[9-(arylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-yl]amines as novel, potent and selective 5-HT₆ receptor antagonistsRamakrishna V S Nirogi, Jagadishu Babu Konda, Ramasastry Kambhampati, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 22, 2017
Erratum to: An RCT Investigating Patient-Driven Versus Physician-Driven Titration of BIAsp 30 in Patients with Type 2 Diabetes Uncontrolled Using NPH InsulinAbdelmjid Chraibi, Shoorook Al-Herz, Bich Dao Nguyen, et al.
Expert Opinion on Investigational Drugs|February 23, 2026
Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist, as a potential treatment for narcolepsy: a phase-2 Drug evaluationRamakrishna Nirogi, Anil Shinde, Ramkumar Subramanian, et al.
Cureus|June 1, 2026
Assessment of Sexual Behaviour Among HIV-Syphilis Coinfected Individuals From Designated Sexually Transmitted Infection/Reproductive Tract Infection (STI/RTI) Clinics in Mumbai, IndiaLatika Shivkar, Shrikala Acharya, Shwetangi R Shinde, et al.
Bioorganic & Medicinal Chemistry Letters|July 5, 2011
Rigidized 1-aryl sulfonyl tryptamines: synthesis and pharmacological evaluation as 5-HT6 receptor ligandsRamakrishna Nirogi, Adireddy Dwarampudi, Ramasastry Kambhampati, et al.
Biomolecules|February 25, 2023
Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain DisordersRamakrishna Nirogi, Pradeep Jayarajan, Anil Shinde, et al.
Neurology and Therapy|July 31, 2022
Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled StudyRamakrishna Nirogi, Vinod Kumar Goyal, Vijay Benade, et al.
Clinical Drug Investigation|August 13, 2022
Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly SubjectsRamakrishna Nirogi, Vijay Benade, Vinod Kumar Goyal, et al.
European Journal of Medicinal Chemistry|January 6, 2016
Benzamide derivatives and their constrained analogs as histamine H3 receptor antagonistsRamakrishna Nirogi, Anil Shinde, Vinaykumar Tiriveedhi, et al.
Behavioural Pharmacology|May 31, 2018
SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterizationRamakrishna Nirogi, Renny Abraham, Vijay Benade, et al.
Bioorganic & Medicinal Chemistry Letters|October 6, 2012
N,N-Dimethyl-[9-(arylsulfonyl)-2,3,4,9-tetrahydro-1H-carbazol-3-yl]amines as novel, potent and selective 5-HT₆ receptor antagonistsRamakrishna V S Nirogi, Jagadishu Babu Konda, Ramasastry Kambhampati, et al.
Pageof 4